Divalent metals and pH alter raltegravir disposition in vitro

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3020-3026

  Moss, Darren M ^a   Siccardi, Marco ^a   Murphy, Matthew ^a   Piperakis, Michael M ^a   Khoo, Saye H ^a   Back, David J ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CALCIUM; MAGNESIUM; METAL DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIVITAMIN; OMEPRAZOLE; RALTEGRAVIR;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL PH; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG EXPOSURE; DRUG PENETRATION; DRUG SOLUBILITY; FOOD DRUG INTERACTION; HUMAN; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; METAL BINDING; MONOLAYER CULTURE; PARTITION COEFFICIENT; PKA; PRIORITY JOURNAL; SCINTILLATION COUNTING; STOMACH PH; TANDEM MASS SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY;

CACO-2 CELLS; CALCIUM; CATIONS, DIVALENT; CELL MEMBRANE; CHROMATOGRAPHY, LIQUID; DRUG INTERACTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MAGNESIUM; OMEPRAZOLE; PYRROLIDINONES; SOLUBILITY; TANDEM MASS SPECTROMETRY;

EID: 84861119863     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06407-11     Document Type: Article

References (27)

1. Brainard DM, et al. 2011. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J. Clin. Pharmacol. 51:422-427.
2. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. 2011. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 51:1376-1402.
3. Cattaneo D, et al. 2011. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J. Antimicrob. Chemother. 67:460-464.
4. Cattaneo D, et al. 2010. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther. Drug Monit. 32:782-786.
5. Charman WN, Porter CJ, Mithani S, Dressman JB. 1997. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 86:269-282. (Pubitemid 27113759)
6. Elsby R, Surry DD, Smith VN, Gray AJ. 2008. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140-1164.
7. Eron J, et al. 2011. QDMRK, a phase III study of the safety and efficacy of once daily vs twice daily RAL in combination therapy for treatment-naïve HIV-infected patients. CROI, Boston, MA.
8. Espeseth AS, et al. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U. S. A. 97:11244-11249.
9. German P, et al. 2009. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir and the pharmacoenhancer GS-9350 as a fixed dose combination tablet, abstr. A1-1300. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. San Francisco, CA.
10. Goodwin JT, Conradi RA, Ho NF, Burton PS. 2001. Physicochemical determinants of passive membrane permeability: role of solute hydrogenbonding potential and volume. J. Med. Chem. 44:3721-3729. (Pubitemid 33026680)
11. Hubatsch I, Ragnarsson EG, Artursson P. 2007. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2:2111-2119. (Pubitemid 351565848)
12. Iwamoto M, et al. 2008. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J. Clin. Pharmacol. 48:209-214.
13. Iwamoto M, et al. 2009. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48:489-492.
14. Kassahun K, et al. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos 35:1657-1663. (Pubitemid 47296061)
15. Kiser JJ, et al. 2010. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob. Agents Chemother. 54:4999-5003.
16. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. 2004. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos. 32:821-827. (Pubitemid 38955611)
17. Loizidou EZ, Kousiappa I, Zeinalipour-Yazdi CD, Van de Vijver DA, Kostrikis LG. 2009. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry 48:4-6.
18. Moss DM, et al. 2011. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 55:879-887.
19. Patel P, et al. 2011. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J. Antimicrob. Chemother. 66:1567-1572.
20. Ramanathan S, Mathias AA, German P, Kearney BP. 2011. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet. 50:229-244.
21. Ramanathan S, Shen G, Hinkle J, Enejosa J, Kearney BP. 2007. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents, abstr. 69. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary.
22. Ramkumar K, Neamati N. 2010. Raltegravir: the evidence of its therapeutic value in HIV-1 infection. Core Evid. 4:131-147.
23. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG. 1998. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J. 17:2699 -2708.
24. Rhame F, et al. 2009. Effects of famotidine and omeprazole on raltegravir pharmacokinetics in HIV-infected individuals, abstr. PE4.1/1. 12th European AIDS Conference, Cologne, Germany.
25. Shelton MJ, Akbari B, Hewitt RG, Adams JM, Morse GD. 2000. Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J. Acquir. Immune Defic. Syndr. 24:79-82. (Pubitemid 30447812)
26. Song I, et al. 2012. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob. Agents Chemother. 56:1627-1629.
27. Wenning LA, et al. 2009. Effect of rifampin, a potent inducer of drugmetabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53:2852-2856.